• 1
    Gossner W, Hug O, Luz A, Muller WA. Experimental induction of bone tumors by short-lived bone-seeking radionuclides. Recent Results Canc Res 1976; 54: 3649.
  • 2
    Rowland RE, Stehney AF, Lucas HF. Dose–response relationship for female radium dial workers. Radiat Res 1978; 76: 36883.
  • 3
    Fry SA. Studies of U.S. radium dial workers: an epidemiological classic. Radiat Res 1986; 150( Suppl): S219.
  • 4
    Spiess H, Mays CW. Bone cancers induced by 224 Ra (Th X) in children and adults. Health Phys 1970; 19: 71329.
  • 5
    Tucker MA, D'Angio GJ, Boice JD,Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 58893.
  • 6
    Newton WA,Jr, Meadows AT, Shimada H, Bunin GR, Vawter GF. Bone sarcomas as second malignant neoplasms following childhood cancer. Cancer 1991; 67: 193201.
  • 7
    Pitcher ME, Davidson TI, Fisher C, Thomas JM. Post irradiation sarcoma of soft tissue and bone. Eur J Surg Oncol 1994; 20: 5356.
  • 8
    Hemminki K, Mutanen P. Genetic epidemiology of multistage carcinogenesis. Mutat Res 2001; 473: 1121.
  • 9
    Balmain A, Nagase H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet 1998; 14: 13944.
  • 10
    Dragani TA, Manenti G, Della Porta G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res 1991; 51: 6299303.
  • 11
    Mock BA, Krall MM, Dosik JK. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA 1993; 90: 9499503.
  • 12
    Zhang SL, DuBois W, Ramsay ES, Bliskovski V, Morse HC,III, Taddesse-Heath L, Vass WC, DePinho RA, Mock BA. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 2001; 21: 31018.
  • 13
    Manenti G, Binelli G, Gariboldi M, Canzian F, De Gregorio L, Falvella FS, Dragani TA, Pierotti MA. Multiple loci affect genetic predisposition to hepatocarcinogenesis in mice. Genomics 1994; 23: 11824.
  • 14
    Saito Y, Ochiai Y, Kodama Y, Tamura Y, Togashi T, Kosugi-Okano H, Miyazawa T, Wakabayashi Y, Hatakeyama K, Wakana S, Niwa O, Kominami R. Genetic loci controlling susceptibility to γ-ray-induced thymic lymphoma. Oncogene 2001; 20: 524347.
  • 15
    Ochiai Y, Tamura Y, Saito Y, Matsuki A, Wakabayashi Y, Aizawa Y, Niwa O, Kominami R. Mapping of genetic modifiers of thymic lymphoma development in p53-knockout mice. Oncogene 2003; 22: 1098102.
  • 16
    Boulton E, Cole C, Knight A, Cleary H, Snowden R, Plumb M. Low-penetrance genetic susceptibility and resistance loci implicated in the relative risk for radiation-induced acute myeloid leukemia in mice. Blood 2003; 101: 234954.
  • 17
    Kodama Y, Yoshikai Y, Tamura Y, Wakana S, Takagi R, Niwa O, Kominami R. The D5Mit7 locus on mouse chromosome 5 provides resistance to γ-ray-induced but not N-methyl-N-nitrosourea-induced thymic lymphomas. Carcinogenesis 2004; 25: 14348.
  • 18
    Rosemann M, Lintrop M, Favor J, Atkinson MJ. Bone tumorigenesis induced by α-particle radiation: mapping of genetic loci influencing predisposition in mice. Radiat Res 2002; 157: 42634.
  • 19
    Muller WA. Studies on short-lived internal-emitters in mice and rats. II. 227 Th. Int J Radiat Biol Relat Stud Phys Chem Med 1971; 20: 23343.
  • 20
    Dietrich WF, Miller JC, Steen RG, Merchant M, Damron D, Nahf R, Gross A, Joycev DC, Wessel M, Dredge RD, Marquis A, Stein LD, et al. A genetic map of the mouse with 4006 simple sequence length polymorphisms. Nat Genet 1994; 7: 22045. ftp/distribution/mouse_sslp_releases/may99/05-99.MarkerInfo.txt
  • 21
    Manly KF, Cudmore RH,Jr, Meer JM. Map Manager QTX, cross-platform software for genetic mapping. Mamm Genome 2001; 12: 93032.
  • 22
    Luz A, Erfle V, Rohmer H, Schetters H, Schafer E, Linzner U, Muller WA, Gossner W. [ CBA- and Balb/c-mice: 2 inbred strains with different susceptibility for the induction of osteosarcoma by Thorium-227]. Verh Dtsch Ges Path 1982; 66: 516.
  • 23
    Luz A, Muller WA, Schaffer E, Murray AB, Linzner U, Gossner W. The sensitivity of female NMRI mice of different ages for osteosarcoma induction with 227thorium. Strahlentherapie [Sonderb] 1985; 80: 17882.
  • 24
    Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995; 11: 2417.
  • 25
    Lloyd RD, Miller SC, Taylor GN, Bruenger FW, Jee WSS, Angus W. Relative effectiveness of 239Pu and some other internal emitters for bone cancer induction in beagles. Health Phys 1994; 67: 34653.
  • 26
    Luz A, Muller WA, Linzner U, Strauss PG, Schmidt J, Muller K, Atkinson MJ, Murray AB, Gossner W, Erfle V, Hofler H. Bone tumor induction after incorporation of short-lived radionuclides. Radiat Environ Biophys 1991; 30: 2257.
  • 27
    Mays CW, Spiess H. Bone sarcoma to man from 224Ra, 226Ra, and 239Pu. In: MullerWA, EvertHG, eds. Biological effects of 224Ra. The Hague: Martinus Nijhoff, 1978. 16881.
  • 28
    Ellenders M, Harrison JD, Pottinger H, Thomas JH. Induction of osteosarcoma and acute myeloid leukaemia in CBA/H mice by the α-emitting nuclides, uranium-233, plutonium-239 and americium-241. Int J Radiat Biol 2001; 77: 4152.
  • 29
    Oghiso Y, Yamada Y. The specific induction of osteosarcomas in different mouse strains after injections of 239Pu citrate. J Radiat Res (Tokyo) 2003; 44: 12532.
  • 30
    Tripodis N, Hart AA, Fijneman RJ, Demant P. Complexity of lung cancer modifiers: mapping of thirty genes and twenty-five interactions in half of the mouse genome. J Natl Cancer Inst 2001; 93: 148491.
  • 31
    Manenti G, Gariboldi M, Fiorino A, Zanesi N, Pierotti MA, Dragani TA. Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res 1997; 57: 41646.
  • 32
    Le Voyer T, Lu Z, Babb J, Lifsted T, Williams M, Hunter K. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome 2000; 11: 8839.
  • 33
    Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer 2001; 93: 15561.
  • 34
    Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003; 11: 61118.
  • 35
    Fearon ER. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278: 104350.
  • 36
    Ponder BA. Inherited predisposition to cancer. Trends Genet 1990; 6: 21328.
  • 37
    Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997; 17: 8891.
  • 38
    Manenti G, Peissel B, Gariboldi M, Falvella FS, Zaffaroni D, Allaria B, Pazzaglia S, Rebessi S, Covelli V, Saran A, Dragani TA. A cancer modifier role for parathyroid hormone-related protein. Oncogene 2000; 19: 532428.
  • 39
    Dragani TA, Hirohashi S, Juji T, Kawajiri K, Kihara M, Ono-Kihara M, Manenti G, Nomoto T, Sugimura H, Genka K, Yokota J, Takahashi T, et al. Population-based mapping of pulmonary adenoma susceptibility 1 locus. Cancer Res 2000; 60: 501720.
  • 40
    Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003; 34: 40312.